Abstract
Importance Glucagon-like peptide-1 (GLP-1) agonists have been proven beneficial in reducing risk of and injury associated with several cardiovascular diseases. The efficacy in cardiopulmonary bypass (CPB)-assisted cardiac surgery is unknown.
Objective This trial aimed to investigate the efficacy of an infusion of the GLP-1 antagonist Exenatide during and after open heart surgery in reducing risk of death and major organ failure.
Design Randomized, double-blinded, 2-by-2 factorial design, clinical trial, also including liberal (FiO2 of 100%) or restrictive (FiO2 of 50%) oxygenation during and after bypass. The present paper presents the results of the Exenatide intervention.
Setting Single site, tertiary heart center.
Participants Adult patients undergoing elective cardiopulmonary bypass-assisted coronary artery bypass grafting and/or aortic valve replacement.
Intervention Infusion of 17.4 µg og Exenatide or placebo during cardiopulmonary bypass and the first hour after weaning thereof
Main outcomes The main outcome was time to a composite endpoint consisting of death, stroke, renal failure requiring dialysis, or new/worsening heart failure during follow-up. Secondary endpoints included occurrence of prespecified adverse events.
Results A total of 1389 patients were included in the analyses. Within a follow-up period of median of 5.9 years (min – max; 2.5 – 8.3 years), 170 patients (24%) in the Exenatide group and 165 patients (24%) experienced a primary endpoint. We found no difference in time to first event between patients randomized to FiO2 50% versus FiO2 100% (HR 1.0 [95%CI 0.83 – 1.3], p = 0.80). We found no significant difference in rates of adverse events between the two groups.
Conclusions and Relevance Exenatide during cardiopulmonary bypass and weaning thereof did not significantly reduce the incidence of death, stroke, renal failure, or new/worsening heart failure in patients undergoing coronary artery bypass grafting and/or aortic valve replacement.
Trial registration
Danish Medicines Agency: Protocol no. HJE-PHARMA-001, EudraCT no. 2015-003050-41, 2nd of October 2015
Local Ethics Committee “Videnskabsetisk komité C, Region Hovedstaden”: No. H-15010562
Trial registrationwww.clinicaltrials.gov: ID no. NCT0267393
Question Is a single dose of Exenatide effectively reducing risk of death or major organ injury in patients undergoing cardiopulmonary bypass (CPB)-assisted cardiac surgery?
Findings 1400 patients undergoing coronary artery bypass grafting and/or aortic valve replacement were randomized to 17,4 µg of Exenatide or placebo during CPB and the first hour after weaning. The hazard ratio (95%CI) for time to the first occurring composite endpoint consisting of death, stroke, renal failure requiring dialysis, and new/worsening heart failure was 1.0 (0.83 – 1.3).
Meaning Exenatide infusion during CPB-assisted cardiac surgery does not improve outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT0267393
Funding Statement
Læge Sofus Carl Emil Friis og Hustru Olga Doris Friis' Legat. 2017 Aase og Ejnar Danielsens Fond 2017, grant no. 10-001976 Danish Heart Foundation 2019, Grant number 19-R133-A9174-22144 The Heart Centre Research Foundation 2017 Lundbeck Foundation (R186-2015-2132)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
1. Danish Medicines Agency: Protocol no. HJE-PHARMA-001, EudraCT no. 2015-003050-41, 2nd of October 2015 2. Local Ethics Committee Videnskabsetisk komité C, Region Hovedstaden: No. H-15010562 3. www.clinicaltrials.gov: ID no. NCT0267393
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Sponsor: Lars Køber, Professor, MD, DMSc, Dept. of Cardiology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark, Lars.Koeber.01{at}regionh.dk
Data Availability
Data can be shared upon request